These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1329 related items for PubMed ID: 18158082

  • 1. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

  • 2. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group.
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [Abstract] [Full Text] [Related]

  • 3. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E, Ezetimibe Study Group.
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [Abstract] [Full Text] [Related]

  • 4. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM.
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y.
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [Abstract] [Full Text] [Related]

  • 6. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y.
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [Abstract] [Full Text] [Related]

  • 7. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
    Geiss HC, Otto C, Parhofer KG.
    Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
    [Abstract] [Full Text] [Related]

  • 8. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D.
    Am J Cardiol; 2007 Jun 15; 99(12):1706-1713. PubMed ID: 17560879
    [Abstract] [Full Text] [Related]

  • 9. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA.
    Metabolism; 2008 Jun 15; 57(6):796-801. PubMed ID: 18502262
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L, Mata P, Gagné C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, Troxell JK, Gumbiner B, Ezetimibe Study Group.
    Clin Ther; 2005 Feb 15; 27(2):174-84. PubMed ID: 15811480
    [Abstract] [Full Text] [Related]

  • 11. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 15; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 12. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan 15; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 13. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
    Zubaid M, Shakir DK, Bazargani N, Binbrek A, Gopal R, Al-Tamimi O, Bakir S.
    J Cardiovasc Med (Hagerstown); 2008 Jul 15; 9(7):688-93. PubMed ID: 18545068
    [Abstract] [Full Text] [Related]

  • 14. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J.
    Am Heart J; 2005 Mar 15; 149(3):464-73. PubMed ID: 15864235
    [Abstract] [Full Text] [Related]

  • 15. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS, Mikhailidis DP.
    Curr Med Res Opin; 2006 Mar 15; 22(3):511-28. PubMed ID: 16574035
    [Abstract] [Full Text] [Related]

  • 16. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
    Bays H, Rhyne J, Abby S, Lai YL, Jones M.
    Curr Med Res Opin; 2006 Nov 15; 22(11):2191-200. PubMed ID: 17076980
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, Maxwell SE, Tiessen R, Cutler DL.
    Curr Med Res Opin; 2004 Aug 15; 20(8):1185-95. PubMed ID: 15324521
    [Abstract] [Full Text] [Related]

  • 18. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia.
    Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C.
    Curr Med Res Opin; 2005 Apr 15; 21(4):571-8. PubMed ID: 15899106
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec 15; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 20. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
    Farnier M, Volpe M, Massaad R, Davies MJ, Allen C.
    Int J Cardiol; 2005 Jul 10; 102(2):327-32. PubMed ID: 15982505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.